Early administration of nirmatrelvir/ritonavir leads to faster negative SARS-CoV-2 nasal swabs than monoclonal antibodies in COVID 19 patients at high-risk for severe disease.
Saved in:
| Title: | Early administration of nirmatrelvir/ritonavir leads to faster negative SARS-CoV-2 nasal swabs than monoclonal antibodies in COVID 19 patients at high-risk for severe disease. |
|---|---|
| Authors: | Colaneri, Marta1,2 (AUTHOR), Scaglione, Giovanni1 (AUTHOR), Fassio, Federico3 (AUTHOR), Galli, Lucia1 (AUTHOR), Lai, Alessia4 (AUTHOR), Bergna, Annalisa4 (AUTHOR), Gabrieli, Arianna4 (AUTHOR), Tarkowski, Maciej4 (AUTHOR), Ventura, Carla Della4 (AUTHOR), Colombo, Valeria5 (AUTHOR), Cordier, Laura1 (AUTHOR), Bernasconi, Davide1 (AUTHOR), Corbellino, Mario6 (AUTHOR), Dedivitiis, Gianfranco1 (AUTHOR), Borghetti, Silvia7 (AUTHOR), Visigalli, Debora7 (AUTHOR), Sollima, Salvatore6 (AUTHOR), Casalini, Giacomo6 (AUTHOR), Rizzardini, Giuliano5 (AUTHOR), Gori, Andrea1,2,4 (AUTHOR) |
| Source: | Virology Journal. 3/20/2024, Vol. 21 Issue 1, p1-6. 6p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1743422X |
|---|---|
| DOI: | 10.1186/s12985-024-02333-x |
